These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 11975844)

  • 1. Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.
    Gupta EK; Ito MK
    Heart Dis; 2002; 4(2):124-37. PubMed ID: 11975844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    Yim BT; Chong PH
    Ann Pharmacother; 2003 Jan; 37(1):106-15. PubMed ID: 12503944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niacin extended-release/lovastatin: combination therapy for lipid disorders.
    Moon YS; Kashyap ML
    Expert Opin Pharmacother; 2002 Dec; 3(12):1763-71. PubMed ID: 12472373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-release niacin/lovastatin: the first combination product for dyslipidemia.
    Bays HE
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):485-501. PubMed ID: 15225109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended-release niacin for modifying the lipoprotein profile.
    Guyton JR
    Expert Opin Pharmacother; 2004 Jun; 5(6):1385-98. PubMed ID: 15163282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of efficacy and safety of fixed dose lovastatin and niacin(ER) combination in asian Indian dyslipidemic patients: a multicentric study.
    Sharma M; Sharma DR; Singh V; Panwar RB; Hira HS; Mohan B; Kumar N; Sharma SK; Gupta R
    Vasc Health Risk Manag; 2006; 2(1):87-93. PubMed ID: 17319473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.
    Chrysant SG; Ibrahim M
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):493-9; quiz 500-1. PubMed ID: 16849903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
    Kashyap ML; McGovern ME; Berra K; Guyton JR; Kwiterovich PO; Harper WL; Toth PD; Favrot LK; Kerzner B; Nash SD; Bays HE; Simmons PD
    Am J Cardiol; 2002 Mar; 89(6):672-8. PubMed ID: 11897208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
    Hunninghake DB; McGovern ME; Koren M; Brazg R; Murdock D; Weiss S; Pearson T
    Clin Cardiol; 2003 Mar; 26(3):112-8. PubMed ID: 12685616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
    Bays HE; McGovern ME
    Prev Cardiol; 2003; 6(4):179-88. PubMed ID: 14605511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
    Karas RH; Kashyap ML; Knopp RH; Keller LH; Bajorunas DR; Davidson MH
    Am J Cardiovasc Drugs; 2008; 8(2):69-81. PubMed ID: 18422390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
    Bays HE; McGovern ME
    Prev Cardiol; 2005; 8(4):226-33. PubMed ID: 16230877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
    Lamon-Fava S; Diffenderfer MR; Barrett PH; Buchsbaum A; Nyaku M; Horvath KV; Asztalos BF; Otokozawa S; Ai M; Matthan NR; Lichtenstein AH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1672-8. PubMed ID: 18566298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
    Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J
    Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    Rubenfire M;
    Am J Cardiol; 2004 Aug; 94(3):306-11. PubMed ID: 15276093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niacin revisited: clinical observations on an important but underutilized drug.
    Henkin Y; Oberman A; Hurst DC; Segrest JP
    Am J Med; 1991 Sep; 91(3):239-46. PubMed ID: 1892143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.